{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.35","value":"20.9"},{"groupId":"OG001","spread":"1.58","value":"25.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"Appetite Loss"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.50","value":"27.4"},{"groupId":"OG001","spread":"1.74","value":"33.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.87","value":"8.0"},{"groupId":"OG001","spread":"1.02","value":"15.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"Cough"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.40","value":"18.8"},{"groupId":"OG001","spread":"1.62","value":"25.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"Shortness of Breath"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.37","value":"0.7"},{"groupId":"OG001","spread":"0.44","value":"1.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"160"}],"units":"Participants"}],"title":"Hemoptysis"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.16","value":"11.6"},{"groupId":"OG001","spread":"1.35","value":"14.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"Pain"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.75","value":"20.5"},{"groupId":"OG001","spread":"2.02","value":"29.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"Total Symptom Distress"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.59","value":"23.6"},{"groupId":"OG001","spread":"1.84","value":"33.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"Normal Activity Status"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.56","value":"27.4"},{"groupId":"OG001","spread":"1.75","value":"35.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"Overall Quality of Life"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.91","value":"14.7"},{"groupId":"OG001","spread":"1.05","value":"19.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"160"}],"units":"Participants"}],"title":"Symptom Burden Index"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.18","value":"19.1"},{"groupId":"OG001","spread":"1.31","value":"24.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"160"}],"units":"Participants"}],"title":"Total Score"}],"denoms":[{"counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"description":"The LCSS consisted of 9 individual items; 6 measured lung cancer symptoms (appetite, fatigue, cough, dyspnea, hemoptysis, and pain); the remaining 3 items measured general lung cancer symptom distress, interference with daily activities and overall QoL. Each item was scored on a 100-millimeter Visual Analogue Scale (VAS), with scores ranging from 0 to 100 (0 = best outcome).\n\nTotal score was calculated as the average of the aggregate score of all 9 items. Scores ranged from 0 to 100, with higher total scores indicating a greater overall impact of symptoms on the patient's QoL. The Symptom Burden Index (SBI) was calculated as the average of the six symptom items. It also ranged from 0 to 100, with higher scores indicating greater symptom burden.\n\nScores were analyzed using repeated measurement model for longitudinal data, including terms for visit, treatment, treatment by time interaction, strata and baseline score. Overall mean and standard error were obtained.","dispersionType":"Standard Error","groups":[{"description":"Ceritinib administered continuously through oral dosing at a dosage of 750 mg once daily in fasted state","id":"OG000","title":"Ceritinib"},{"description":"Pemetrexed plus cisplatin or carboplatin (based on Investigator's choice) for 4 cycles (Induction) followed by pemetrexed as single agent (Maintenance)","id":"OG001","title":"Chemotherapy"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The Full Analysis Set (FAS) consisted of all patients to whom study treatment had been assigned by randomization. Participants with a baseline assessment for at least one of the domain scores","reportingStatus":"POSTED","timeFrame":"Screening, treatment phase (Cycles 2, 3 then every 2nd cycle until Month 33; after Month 33, every 9 or 12 weeks, end of treatment); follow-up phase (Every 6 weeks until Month 33; after Month 33 every 9 or 12 weeks) up to approximately 120 months","title":"Least Squares Mean Scores on the Lung Cancer Symptom Scale (LCSS)","type":"SECONDARY","unitOfMeasure":"Score on a Scale"}